Adverum Biotechnologies Price Target, Predictions & Analyst Ratings

-0.11 (-4.62 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume2.23 million shs
Average Volume2.34 million shs
Market Capitalization$222.30 million
P/E RatioN/A
Dividend YieldN/A

Adverum Biotechnologies (NASDAQ:ADVM) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
11 Wall Street analysts have issued ratings and price targets for Adverum Biotechnologies in the last 12 months. Their average twelve-month price target is $9.38, predicting that the stock has a possible upside of 313.00%. The high price target for ADVM is $30.00 and the low price target for ADVM is $2.00. There are currently 10 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
TypeToday30 Days Ago90 Days Ago180 Days Ago
ADVM Consensus Rating: HoldHoldHoldBuy
ADVM Consensus Rating Score:
ADVM Analyst Ratings: 0 Sell Rating(s)
10 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
ADVM Consensus Price Target: $9.38$14.13$14.89$23.50
ADVM Price Target Upside: 313.00% upside51.36% upside33.85% upside34.52% upside

Adverum Biotechnologies (NASDAQ:ADVM) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Adverum Biotechnologies (NASDAQ:ADVM) Analyst Ratings History

DateBrokerageAnalyst NameActionRatingPrice TargetDetails
7/30/2021Royal Bank of Canada
Reiterated RatingHold$6.00
7/23/2021The Goldman Sachs Group
DowngradeBuy ➝ Neutral
7/23/2021SVB Leerink
M. Foroohar
Lower Price TargetMarket Perform$5.00 ➝ $2.00
7/23/2021Chardan Capital
Y. Livshits
Lower Price TargetNeutral$5.00 ➝ $3.00
7/23/2021Cantor Fitzgerald
A. Young
DowngradeOverweight ➝ Neutral$23.00 ➝ $3.00
5/5/2021Truist Securities
Reiterated RatingBuy ➝ Hold$30.00 ➝ $9.00
4/29/2021Lifesci Capital
P. Dolezal
DowngradeOutperform ➝ Market Perform
12/15/2020UBS Group
Initiated CoverageNeutral$13.00
11/12/2020Raymond James
Dane Leone
UpgradeUnderperform ➝ Market Perform
8/10/2020Piper Sandler
Boost Price TargetOverweight$25.00 ➝ $30.00
5/5/2020SunTrust Banks
UpgradeHold ➝ Buy$13.00 ➝ $21.00
1/13/2020Piper Jaffray Companies
Boost Price TargetOverweight$14.00 ➝ $20.00
Reiterated RatingBuy
(Data available from 8/1/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
This page was last updated on 8/1/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.